FDA approves SymlinPen

FDA approved the SymlinPen 120 and SymlinPen 60 pen-injector devices from Amylin (AMLN) for administration of Symlin pramlintide. The synthetic amylin analog is approved for use in conjunction with insulin at mealtime to treat Type I and Type II diabetes in patients who have not achieved desired glucose control. AMLN said it expects the pens to be available by December. ...